Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Grape compound resveratrol tested in teens with diabetic kidney disease

NCT ID NCT07332819

Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether resveratrol, a natural substance found in grapes and peanuts, could improve blood sugar control and kidney health in 60 teenagers with type 1 diabetes and early kidney damage. Participants took resveratrol tablets twice daily for 6 months. The study measured changes in blood sugar levels, cholesterol, and a kidney injury marker. Results may show if this supplement offers a safe, additional way to manage diabetes complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

60 people

The number who actually took part.

Started

Jul 2024

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with T1DM. * Patients aged 12-18 years with at least 5 years disease duration. * Active diabetic nephropathy in the form of microalbuminuria (urinary albumin excretion \[UAE\] 30-299 mg/g creatinine). The presence of persistent microalbuminuria was confirmed by finding two or all of three samples abnormal over a 3- to 6-months period prior to study despite angiotensin converting enzyme inhibitors (ACE-Is) (Tabaei et al., 2001; Molitch et al., 2004; Donaghueet al., 2018). * Hemoglobin A1c (HbA1c) ≤9.0%. * Patients on regular visit to clinic. * Patients on regular insulin therapy. Exclusion Criteria: * Patients with history of liver disease or any disorder likely to impair liver functions or elevated liver enzymes (aminotransferases levels higher than twice the upper normal limit). * Patients with renal impairment due to cause other than diabetes. * Patients with hypertension. * Hyper- or hypo-thyroidism. * Hepatitis virus infection (B or C) or any evidence of infection. * Hypoglycaemic unawareness or recurrent severe hypoglycaemic episode in 6 months prior to recruitment. * Recurrent diabetic ketoacidosis (more than 2 episodes in the previous 12 months). * Serious co-morbidities. * Patients were already on anti-hypertensive drugs or any antioxidant therapy such as vitamin supplements. * Taking any vitamins or food supplements one month before study. * Patients who have an allergy to grapes, berries, and peanuts. * Participation in a previous investigational drug study within 3 months preceding screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetic nephropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetic kidney disease kidney disorder type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 1 diabetic nephropathy

Contacts and locations

Locations

  • Faculty of Medicine, Ain Shams University

    Cairo, Egypt